NCT03949985

Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives

Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives: a Prospective Cohort Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 103 (actual)
• Sponsor: University Hospital, Geneva · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: —

Summary

This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during the first 3 months after having stopped a combined oral contraceptive.

Detailed description

Women using a combined oral contraceptive (COC) and who have decided to stop it or switch it to a non-estrogenic contraceptive are included. At baseline, before the COC is stopped, and at multiple time points during the 3 months of follow-up, blood will be drawn to evaluate the hemostatic profile. Findings are compared with a control group of women without an estrogenic contraceptive, who are also followed for 3 months.

Conditions

• Venous Thromboembolism
• Contraception

Interventions

Type	Name	Description
OTHER	Tests of biological hemostatic profile associated with contraceptives	Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)

Timeline

• Start date: 2018-10-08
• Primary completion: 2020-09-14
• Completion: 2020-09-14
• First posted: 2019-05-14
• Last updated: 2021-05-21

Locations

1 site across 1 country: Switzerland

Regulatory

• FDA-regulated drug study